Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1991 5
1992 4
1993 2
1994 4
1995 2
1998 4
1999 2
2000 4
2001 5
2002 4
2003 13
2004 9
2005 7
2006 4
2007 9
2008 10
2009 7
2010 11
2011 15
2012 13
2013 9
2014 12
2015 16
2016 19
2017 20
2018 15
2019 18
2020 11
2021 15
2022 6
2023 8
2024 12
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

273 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA; ORAL Surveillance Investigators. Ytterberg SR, et al. N Engl J Med. 2022 Jan 27;386(4):316-326. doi: 10.1056/NEJMoa2109927. N Engl J Med. 2022. PMID: 35081280 Clinical Trial.
2018 update of the EULAR recommendations for the management of Behçet's syndrome.
Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gul A, Kötter I, Leccese P, Mahr A, Moots R, Ozguler Y, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H. Hatemi G, et al. Among authors: moots r. Ann Rheum Dis. 2018 Jun;77(6):808-818. doi: 10.1136/annrheumdis-2018-213225. Epub 2018 Apr 6. Ann Rheum Dis. 2018. PMID: 29625968
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ, Fox R, Dörner T, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki JN, Sopala MA, Luo WL, Hueber W. Bowman SJ, et al. Among authors: moots rj. Lancet. 2022 Jan 8;399(10320):161-171. doi: 10.1016/S0140-6736(21)02251-0. Epub 2021 Nov 30. Lancet. 2022. PMID: 34861168 Clinical Trial.
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.
Rivellese F, Surace AEA, Goldmann K, Sciacca E, Çubuk C, Giorli G, John CR, Nerviani A, Fossati-Jimack L, Thorborn G, Ahmed M, Prediletto E, Church SE, Hudson BM, Warren SE, McKeigue PM, Humby F, Bombardieri M, Barnes MR, Lewis MJ, Pitzalis C; R4RA collaborative group. Rivellese F, et al. Nat Med. 2022 Jun;28(6):1256-1268. doi: 10.1038/s41591-022-01789-0. Epub 2022 May 19. Nat Med. 2022. PMID: 35589854 Free PMC article. Clinical Trial.
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study.
Dörner T, Bowman SJ, Fox R, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki J, Sopala M, Avrameas A, Luo WL, Hueber W. Dörner T, et al. Among authors: moots rj. Arthritis Rheumatol. 2025 May;77(5):560-570. doi: 10.1002/art.43059. Epub 2025 Jan 5. Arthritis Rheumatol. 2025. PMID: 39557617 Clinical Trial.
Pain Reduction With Oral Methotrexate in Knee Osteoarthritis : A Randomized, Placebo-Controlled Clinical Trial.
Kingsbury SR, Tharmanathan P, Keding A, Watt FE, Scott DL, Roddy E, Birrell F, Arden NK, Bowes M, Arundel C, Watson M, Ronaldson SJ, Hewitt C, Doherty M, Moots RJ, O'Neill TW, Green M, Patel G, Garrood T, Edwards CJ, Walmsley PJ, Sheeran T, Torgerson DJ, Conaghan PG. Kingsbury SR, et al. Among authors: moots rj. Ann Intern Med. 2024 Sep;177(9):1145-1156. doi: 10.7326/M24-0303. Epub 2024 Jul 30. Ann Intern Med. 2024. PMID: 39074374 Clinical Trial.
Behcet's disease.
Nair JR, Moots RJ. Nair JR, et al. Among authors: moots rj. Clin Med (Lond). 2017 Feb;17(1):71-77. doi: 10.7861/clinmedicine.17-1-71. Clin Med (Lond). 2017. PMID: 28148585 Free PMC article.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators. Fleischmann R, et al. Among authors: moots rj. Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16. Lancet. 2017. PMID: 28629665 Clinical Trial.
British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behçets 2024.
Murphy R, Moots RJ, Brogan P, Çelik AF, Clement-Jones M, Coulson I, Croft AP, Crozier S, Forrest L, Harrold J, Higgins S, Jawad ASM, Kalra S, Khan SS, McKee H, Pain CE, Petrushkin H, Poveda-Gallego A, Setterfield J, Sharma P, West R, Wlodek C, Hashme M, Manounah L, Mohd Mustapa MF, Constantin AM. Murphy R, et al. Among authors: moots rj. Br J Dermatol. 2024 Oct 17;191(5):e8-e25. doi: 10.1093/bjd/ljae263. Br J Dermatol. 2024. PMID: 39253835 No abstract available.
273 results